Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) and LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Sunshine Biopharma and LENZ Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 1 | 1 | 0 | 0 | 1.50 |
| LENZ Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
LENZ Therapeutics has a consensus price target of $23.00, suggesting a potential upside of 597.82%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Sunshine Biopharma.
Profitability
This table compares Sunshine Biopharma and LENZ Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -17.94% | -26.36% | -20.60% |
| LENZ Therapeutics | -586.74% | -53.39% | -49.14% |
Volatility & Risk
Sunshine Biopharma has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Insider & Institutional Ownership
42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 1.7% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Sunshine Biopharma and LENZ Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sunshine Biopharma | $36.31 million | 0.03 | -$5.97 million | ($10.15) | -0.02 |
| LENZ Therapeutics | $19.09 million | 5.42 | -$82.13 million | ($4.09) | -0.81 |
Sunshine Biopharma has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
